Efficacy and safety of ivosidenib in Australian and South Korean patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): focus on long responders from the phase 3b ProvIDHe study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #354P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • P3 data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • IDH1
|
|
Hao-Wen Sim; Jung Yong Hong; Choong-kun Lee; Kyu-pyo Kim; Melissa Eastgate; Hong Jae Chon; Sue-Anne McLachlan; Do-Youn Oh; Timothy J. Price; Victor Manuel Minguez; Renata Robert; Junxian Geng; Teresa Macarulla Mercade; Arndt Vogel; Lorenza Rimassa
|